Cancer treatment -- chemotherapy, radiation, surgery, and their combinations -- produces a range of physical effects that can significantly affect walking ability. These are distinct from the cancer itself: the treatment-induced effects are the primary cause of mobility limitation for many cancer survivors. A walking cane is increasingly recognised as a useful tool during cancer treatment and recovery, yet it remains underutilised because the connection between oncology care and mobility aid prescription is often poorly coordinated.
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
CIPN is among the most common side effects of taxane, platinum, and vinca alkaloid chemotherapy. It produces numbness, tingling, and sometimes pain in the feet and hands -- and critically, it impairs proprioception. The result is an increased fall risk that is well-documented and underaddressed.
A walking cane in CIPN provides the same function as in diabetic neuropathy or CMT: an additional proprioceptive input through the handle that supplements the reduced lower limb sensory signal. For patients on chemotherapy who have developed CIPN, a cane is appropriate and has the same fall-prevention value as in other neuropathic conditions.
CIPN: 3mm wet tip slip (Steady Tip) versus 14-18mm (generic) matters when foot sensation is impaired and the patient cannot rely on foot proprioception to detect a slipping surface.
Cancer-Related Fatigue (CRF)
Cancer-related fatigue is the most common side effect of cancer treatment, reported by 70-100% of patients receiving chemotherapy or radiation. Unlike normal fatigue, CRF does not resolve with rest and can persist for months or years after treatment ends. A cane reduces the effort of each step, extending the functional walking range before CRF limits activity.
For CRF, the cane specifications that reduce fatigue are most relevant: low vibration (wood shaft: 25-60x less than aluminium), low grip force required (Anatomic Grip: 1.9 N/cm2), and light enough not to add significantly to the carrying burden.
Bone Metastases and Walking Safety
For patients with bone metastases, particularly in the femur, pelvis, or vertebrae, walking load management is clinically critical. Pathological fracture from a bone met is a serious complication. A walking cane reduces load through affected bone areas in the lower limb by 15-25% per step. For femoral metastases, the orthopaedic oncologist should specify the appropriate weight-bearing level -- a single cane may be insufficient for high-risk femoral mets (prophylactic fixation is sometimes required).
Post-Surgical Oncological Cases
Surgical cancer treatment affecting mobility includes: limb-sparing surgery for bone or soft tissue sarcoma, pelvic/hip surgery for gynaecological cancers, and lymph node dissection affecting lower limb drainage (lymphoedema of the lower limb alters gait mechanics). Each has specific post-surgical weight-bearing and cane use protocols that should be specified by the surgical team.
Steroid-Induced Myopathy
High-dose corticosteroids, used widely in oncology (dexamethasone for nausea, brain oedema, airway inflammation), cause proximal muscle weakness (steroid myopathy). This is the same mechanism as in long-term steroid use for polymyalgia rheumatica or other inflammatory conditions -- hip and thigh weakness that impairs walking. A cane provides stability support during steroid myopathy, which typically improves when steroids are weaned.
| Treatment Effect | Cane Function | Specification Priority |
|---|---|---|
| CIPN (neuropathy) | Proprioceptive supplement, fall prevention | Steady Tip (large contact), 0mm shaft play |
| Cancer-related fatigue | Reduces per-step effort | Wood shaft (low vibration), Anatomic Grip |
| Bone metastases | Load reduction through affected bone | Solid shaft, per oncological guidance |
| Steroid myopathy | Stability during proximal weakness | Standard cane specifications |
View the DaiWalk range for oncology-appropriate cane specifications covering CIPN, fatigue, and bone metastasis load management.
